Description

HGH Fragment 176-191 2mg – Human Growth Hormone Research Peptide

HGH Fragment 176-191 2mg is a synthetic research peptide corresponding to the C-terminal 16-amino-acid region of human growth hormone. The fragment has attracted scientific interest through investigations into lipid metabolism, adipose tissue biology and the relationship between growth hormone structure and metabolic activity.

HGH Fragment 176-191 2mg is associated with research into the biological functions of specific regions of human growth hormone. Unlike full-length growth hormone, which contains 191 amino acid residues, this fragment represents only a short section of the complete protein.

Early experimental research investigated whether peptides derived from the C-terminal region of human growth hormone could influence lipid metabolism without reproducing all the growth-related effects of the intact hormone. However, much of the published evidence involves related fragments or the modified analogue AOD-9604 rather than the exact native HGH Fragment 176-191 sequence.

HGH Fragment 176-191 2mg remains an investigational research material. There is insufficient reliable human clinical evidence establishing its safety or effectiveness for weight loss, fat reduction, muscle growth or metabolic disease.

What Is HGH Fragment 176-191 2mg?

HGH Fragment 176-191 2mg refers to a product labelled as containing 2mg of a synthetic peptide corresponding to amino acid residues 176 through 191 of mature human growth hormone.

Human growth hormone, also called somatotropin, is a 191-amino-acid protein produced by the anterior pituitary gland.

It participates in growth, metabolism and the regulation of several physiological processes.

The C-terminal region of human growth hormone became a subject of research because experimental studies suggested that selected peptide fragments could influence lipid metabolism.

The native HGH Fragment 176-191 sequence contains 16 amino acid residues.

It should not automatically be identified as AOD-9604 because AOD-9604 contains a modified N-terminal amino acid.

HGH Fragment 176-191 2mg Product Specifications

• Product Name: HGH Fragment 176-191 2mg
• Alternative Name: Human Growth Hormone Fragment 176-191
• Compound Classification: Synthetic growth hormone-derived research peptide
• Peptide Type: C-terminal hexadecapeptide
• Reference Sequence: Phe-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe
• One-Letter Sequence: FLRIVQCRSVEGSCGF
• Peptide Length: 16 amino acid residues
• Reference Molecular Formula: C78H123N23O22S2, for the disulfide-bonded free peptide
• Reference Molecular Weight: Approximately 1799.1 g/mol, for the disulfide-bonded free peptide
• Commonly Listed CAS Number: 66004-57-7
• Labelled Quantity: 2mg
• Research Category: Peptide biochemistry and metabolic research
• Research Focus: Lipid metabolism, adipose tissue biology and growth hormone fragments
• Disulfide Bond: Between the two cysteine residues in the reference cyclic structure
• Purity: Requires batch-specific verification
• Salt Form: Confirm with manufacturer
• Physical Form: Confirm with manufacturer
• Storage: Follow verified manufacturer instructions
• Intended Use: Laboratory research only

These specifications describe the native disulfide-bonded HGH Fragment 176-191 molecule. Commercial products may be labelled inconsistently, and some suppliers use the HGH Fragment 176-191 name for AOD-9604. The exact sequence, molecular mass and salt form should therefore be confirmed using batch-specific analytical documentation.

Understanding the Molecular Structure of HGH Fragment 176-191

HGH Fragment 176-191 is a synthetic peptide corresponding to the final 16 amino acid residues of mature human growth hormone.

Its native reference sequence is:

FLRIVQCRSVEGSCGF

The sequence includes phenylalanine, leucine, arginine, isoleucine, valine, glutamine, cysteine, serine, glutamic acid and glycine residues.

Two cysteine residues can form an intramolecular disulfide bond, producing a cyclic structural feature.

This bond is relevant to the peptide’s conformation and analytical characterisation.

Researchers should verify whether a supplied HGH Fragment 176-191 2mg preparation contains the oxidised disulfide-bonded structure or a different chemical form.

How Does HGH Fragment 176-191 Work?

HGH Fragment 176-191 has been investigated in relation to lipid metabolism and the biological activity of the C-terminal region of human growth hormone.

Early research involving related growth hormone fragments examined their effects on lipolysis and lipid accumulation in experimental systems.

Lipolysis refers to the breakdown of stored triglycerides into fatty acids and glycerol.

Researchers have also investigated the possible involvement of adrenergic signalling pathways in the metabolic effects of related growth hormone-derived peptides.

However, important mechanistic findings involve AOD-9604 or other related fragments rather than the exact native HGH Fragment 176-191 molecule.

The complete mechanism of action of native HGH Fragment 176-191 remains insufficiently established.

It should not be described as a proven selective fat-burning agent.

Scientific Research Into HGH Fragment 176-191 2mg

1. HGH Fragment 176-191 2mg and Lipolysis Research

Lipolysis is a metabolic process through which stored triglycerides are broken down into fatty acids and glycerol.

Growth hormone participates in the regulation of lipid metabolism.

Researchers have investigated whether selected fragments of the growth hormone molecule retain particular metabolic properties.

Early laboratory studies involving C-terminal growth hormone fragments reported effects on lipid-related measurements.

However, these findings do not establish that HGH Fragment 176-191 2mg safely produces fat loss in humans.

2. HGH Fragment 176-191 and Adipose Tissue Research

Adipose tissue stores energy and participates in endocrine and metabolic signalling.

It contains adipocytes, vascular cells, immune cells and supporting tissue structures.

Experimental research involving growth hormone-derived fragments has examined changes in adipose tissue metabolism.

These investigations contributed to interest in the C-terminal region of human growth hormone.

However, findings involving related fragments cannot automatically establish the biological effects of native HGH Fragment 176-191.

3. HGH Fragment 176-191 2mg and Growth Hormone Structure Research

Human growth hormone is a protein composed of 191 amino acid residues.

Its biological effects depend on its complete molecular structure and interactions with specific receptors.

Researchers have investigated smaller fragments to identify regions associated with selected biological activities.

HGH Fragment 176-191 represents one such region.

However, the fragment does not reproduce the complete structure or pharmacology of full-length human growth hormone.

4. HGH Fragment 176-191 and Growth Hormone Receptor Research

The growth hormone receptor is involved in many of the biological effects of full-length growth hormone.

Receptor activation influences intracellular signalling pathways associated with growth and metabolism.

HGH Fragment 176-191 lacks much of the structural architecture required for the normal receptor interactions of the complete hormone.

Researchers should therefore avoid assuming that the fragment has the same receptor activity as full-length growth hormone.

Direct receptor-binding and functional evidence should be evaluated separately for each peptide.

5. HGH Fragment 176-191 2mg and IGF-1 Research

Insulin-like growth factor 1, commonly abbreviated IGF-1, participates in growth hormone-related signalling.

Full-length growth hormone can influence IGF-1 production.

However, this does not establish that HGH Fragment 176-191 produces the same effect.

Research involving AOD-9604 has reported differences from full-length growth hormone in growth-related signalling.

Those findings should not automatically be attributed to the native HGH Fragment 176-191 peptide.

6. HGH Fragment 176-191 and Lipid Storage Research

Lipid storage involves the accumulation of triglycerides within adipocytes.

Researchers have examined whether growth hormone-derived fragments influence lipid accumulation in experimental systems.

Some early studies involving related fragments reported changes in lipid storage measurements.

However, these observations require careful interpretation because experimental conditions differ across studies.

There is insufficient clinical evidence that HGH Fragment 176-191 2mg reliably prevents fat accumulation in humans.

7. HGH Fragment 176-191 2mg and Obesity Research

Obesity is a complex chronic condition involving metabolic, genetic, environmental and behavioural factors.

Growth hormone-derived peptides have been investigated as possible subjects for metabolic research.

However, the strongest human obesity development programme involved AOD-9604 rather than native HGH Fragment 176-191.

The AOD-9604 programme did not establish sufficient weight-loss effectiveness for regulatory approval.

These findings cannot be used to claim that HGH Fragment 176-191 2mg is an effective obesity treatment.

8. HGH Fragment 176-191 and Glucose Metabolism Research

Glucose metabolism is regulated by insulin, glucagon and several other hormones.

Full-length growth hormone can influence insulin sensitivity and glucose regulation.

Historical animal research involving native C-terminal growth hormone fragments reported changes in blood glucose, insulin and insulin sensitivity.

These findings caution against assuming that the native fragment has no effects on glucose metabolism.

HGH Fragment 176-191 2mg has not been established as a safe treatment for insulin resistance or diabetes.

9. HGH Fragment 176-191 2mg and Insulin Sensitivity Research

Insulin sensitivity describes how effectively tissues respond to insulin.

It is an important component of metabolic regulation.

Early animal studies involving growth hormone fragments examined changes in insulin-related responses.

Selected fragments produced measurable effects on insulin sensitivity under experimental conditions.

However, these results do not establish a predictable or beneficial response in humans.

10. HGH Fragment 176-191 and Beta-Adrenergic Research

Beta-adrenergic receptors participate in physiological responses involving metabolism and sympathetic nervous system signalling.

Research involving AOD-9604 investigated the involvement of beta-3 adrenergic receptors in selected metabolic effects.

However, this evidence primarily concerns the modified AOD-9604 compound.

It should not be presented as definitive proof that native HGH Fragment 176-191 acts through an identical mechanism.

11. HGH Fragment 176-191 2mg and Peptide Structure-Activity Research

Structure-activity relationship research investigates how changes in molecular structure influence biological properties.

HGH Fragment 176-191 provides a useful reference for comparing native growth hormone sequences with chemically modified analogues.

AOD-9604 differs from the native fragment through an N-terminal phenylalanine-to-tyrosine substitution.

This structural difference changes the peptide’s molecular formula and mass.

Researchers should distinguish these compounds when interpreting analytical results and experimental findings.

12. HGH Fragment 176-191 and Disulfide Bond Research

Disulfide bonds form when two cysteine residues become linked through oxidation.

They can influence peptide conformation and molecular stability.

The reference cyclic structure of HGH Fragment 176-191 contains an intramolecular disulfide bond.

Researchers should verify the oxidation state of the supplied peptide when characterising HGH Fragment 176-191 2mg.

Different oxidation states may produce different analytical and biological properties.

13. HGH Fragment 176-191 2mg and Peptide Stability Research

Peptide stability depends on amino acid composition, chemical modifications, environmental conditions and formulation.

HGH Fragment 176-191 contains a defined sequence and disulfide-bonded structural feature.

Researchers may investigate how these characteristics influence stability under controlled laboratory conditions.

However, the stability of a commercial HGH Fragment 176-191 2mg preparation cannot be established without product-specific data.

14. HGH Fragment 176-191 and Molecular Identification Research

Molecular identification is essential when working with closely related research peptides.

HGH Fragment 176-191 and AOD-9604 differ by a single oxygen atom in their free disulfide-bonded forms.

This produces a molecular mass difference of approximately 16 Da.

Mass spectrometry and appropriate chromatographic methods can help distinguish these compounds.

Researchers should verify the actual supplied sequence rather than relying exclusively on a product name.

15. HGH Fragment 176-191 2mg and Research Reproducibility

Scientific reproducibility depends on accurate identification of experimental materials.

Research results may differ when laboratories use compounds with different amino acid sequences, salt forms or purity profiles.

Confusion between native HGH Fragment 176-191 and AOD-9604 can affect the interpretation of published studies.

Researchers should confirm the exact chemical identity of HGH Fragment 176-191 2mg before comparing results across experimental systems.

HGH Fragment 176-191 2mg vs AOD-9604

HGH Fragment 176-191 and AOD-9604 are closely related but chemically distinct peptides.

• HGH Fragment 176-191: Native C-terminal sequence FLRIVQCRSVEGSCGF.
• AOD-9604: Modified sequence YLRIVQCRSVEGSCGF.
• Structural Difference: The native fragment begins with phenylalanine, while AOD-9604 begins with tyrosine.
• Reference Molecular Weight: Approximately 1799.1 g/mol for the native disulfide-bonded fragment and 1815.1 g/mol for AOD-9604.
• Clinical Evidence: AOD-9604 underwent human obesity trials; comparable clinical evidence is not established for the native fragment.

Researchers should not treat these names as interchangeable when recording chemical specifications or interpreting research outcomes.

HGH Fragment 176-191 2mg vs Full-Length HGH

HGH Fragment 176-191 and full-length human growth hormone differ substantially in molecular size and structure.

Full-length human growth hormone contains 191 amino acid residues.

HGH Fragment 176-191 contains only 16 amino acid residues.

Full-length growth hormone participates in established receptor-mediated growth and metabolic signalling.

The fragment does not reproduce the complete hormone’s structure or established clinical effects.

Findings involving prescribed growth hormone medicines should not be attributed to HGH Fragment 176-191 2mg.

HGH Fragment 176-191 2mg vs CJC-1295

HGH Fragment 176-191 and CJC-1295 are different research peptides.

HGH Fragment 176-191 is derived from the C-terminal region of human growth hormone.

CJC-1295 is a modified growth hormone-releasing hormone analogue.

These compounds have different molecular structures and research mechanisms.

Results involving CJC-1295 cannot establish the safety or effectiveness of HGH Fragment 176-191.

HGH Fragment 176-191 2mg and Fat-Loss Claims

HGH Fragment 176-191 2mg is frequently described online as a fat-loss peptide.

However, there is insufficient reliable human clinical evidence demonstrating that the native fragment safely reduces body fat or produces clinically meaningful weight loss.

Much of the research commonly cited in marketing involves related fragments or AOD-9604.

These findings should not be presented as direct proof of effectiveness for the native HGH Fragment 176-191 peptide.

HGH Fragment 176-191 2mg and Muscle Growth Claims

HGH Fragment 176-191 2mg is not an established muscle-building treatment.

Its short peptide sequence differs substantially from full-length human growth hormone.

There is insufficient reliable clinical evidence that HGH Fragment 176-191 safely increases muscle mass, strength or athletic performance.

Understanding the HGH Fragment 176-191 2mg Label

The 2mg designation refers to the labelled quantity of research material.

It does not represent a recommended human dose or independently establish peptide purity, identity, sterility or biological activity.

Researchers should verify whether the stated mass refers to the free peptide or includes counterions and other formulation components.

HGH Fragment 176-191 2mg Research Quality and Documentation

Important considerations when evaluating HGH Fragment 176-191 2mg include:

• Verification of the complete FLRIVQCRSVEGSCGF sequence
• Confirmation of the native N-terminal phenylalanine residue
• Distinction from the tyrosine-containing AOD-9604 analogue
• Verification of the 16-amino-acid structure
• Confirmation of the disulfide-bonded molecular form
• Verification of the expected molecular mass
• Identification of the supplied salt form
• Batch-specific certificate of analysis
• Appropriate analytical purity testing
• Mass spectrometry or another suitable identity method
• Confirmation of the labelled 2mg quantity
• Assessment of synthesis-related impurities
• Manufacturer and batch traceability
• Verified packaging specifications
• Product-specific storage and stability information
• Clearly stated research-use classification

Storage and Handling of HGH Fragment 176-191 2mg

HGH Fragment 176-191 2mg should be stored according to verified manufacturer instructions.

Storage requirements depend on the peptide’s salt form, physical presentation, formulation and packaging.

Researchers should not assume that all growth hormone fragment preparations have identical stability or shelf-life characteristics.

Laboratory handling should follow relevant safety documentation and institutional procedures.

HGH Fragment 176-191 2mg Safety and Scientific Limitations

HGH Fragment 176-191 2mg is an investigational research material without an established human clinical safety profile.

There is insufficient reliable evidence demonstrating its effectiveness for weight loss, obesity treatment or metabolic disease.

Historical animal studies involving native growth hormone fragments reported changes in glucose, insulin and insulin sensitivity.

These findings caution against assuming that the native fragment has no metabolic or endocrine risks.

Additional uncertainties include long-term toxicity, human pharmacokinetics, immune responses and the consequences of repeated exposure.

HGH Fragment 176-191 is not an established approved medicine for obesity, fat loss, muscle growth or anti-ageing in the United Kingdom.

Research-grade material should not be assumed suitable for human administration.

This information is intended for scientific and educational purposes only and does not provide human dosing recommendations or administration instructions.

Frequently Asked Questions About HGH Fragment 176-191 2mg

What is HGH Fragment 176-191 2mg?

HGH Fragment 176-191 2mg is a product listing for a synthetic 16-amino-acid peptide corresponding to the C-terminal region of human growth hormone.

What is the HGH Fragment 176-191 peptide sequence?

The native reference sequence is FLRIVQCRSVEGSCGF.

How many amino acids does HGH Fragment 176-191 contain?

The native fragment contains 16 amino acid residues.

What is the molecular formula of HGH Fragment 176-191?

The disulfide-bonded free peptide has the reference molecular formula C78H123N23O22S2.

What is the molecular weight of HGH Fragment 176-191?

The reference molecular weight is approximately 1799.1 g/mol for the native disulfide-bonded free peptide.

What is the CAS number for HGH Fragment 176-191?

A commonly listed CAS number is 66004-57-7. Researchers should verify the identifier against the exact supplied molecular form.

Is HGH Fragment 176-191 the same as AOD-9604?

No. The native fragment begins with phenylalanine, while AOD-9604 begins with tyrosine.

Does HGH Fragment 176-191 burn fat?

There is insufficient reliable human clinical evidence that the native fragment safely produces meaningful fat loss.

Does HGH Fragment 176-191 increase growth hormone?

The fragment is not established as a growth hormone secretagogue and should not be assumed to reproduce the effects of full-length growth hormone.

Does HGH Fragment 176-191 affect IGF-1?

Its effects on IGF-1 in humans have not been adequately established.

Does HGH Fragment 176-191 affect blood glucose?

Historical animal research involving native growth hormone fragments reported changes in glucose and insulin-related measurements. Human effects remain uncertain.

Is HGH Fragment 176-191 approved for weight loss?

No. HGH Fragment 176-191 is not an established approved UK weight-loss medicine.

What does HGH Fragment 176-191 2mg mean?

The designation refers to a labelled quantity of 2mg of research material, not a recommended human dose.

HGH Fragment 176-191 2mg – Scientific Product Summary

HGH Fragment 176-191 2mg is a synthetic peptide corresponding to the native C-terminal 16-amino-acid sequence of human growth hormone.

Its reference sequence is FLRIVQCRSVEGSCGF, with a disulfide-bonded free peptide molecular weight of approximately 1799.1 g/mol.

Research involving the C-terminal region of human growth hormone has examined lipid metabolism and adipose tissue biology, although much of the available evidence concerns related fragments or AOD-9604.

Human therapeutic effectiveness and long-term safety remain insufficiently established.

Researchers evaluating HGH Fragment 176-191 2mg should verify the complete peptide sequence, molecular identity, purity, salt form, labelled quantity and batch-specific analytical documentation.